GATA2 mutated allele specific expression is associated with a hyporesponsive state of HSC in GATA2 deficiency syndrome - Takeaways - MDSpire

GATA2 mutated allele specific expression is associated with a hyporesponsive state of HSC in GATA2 deficiency syndrome

  • By

  • Laetitia Largeaud

  • Vincent Fregona

  • Laura A. Jamrog

  • Camille Hamelle

  • Stéphanie Dufrechou

  • Naïs Prade

  • Esmaa Sellam

  • Pauline Enfedaque

  • Manon Bayet

  • Sylvie Hébrard

  • Mathieu Bouttier

  • Christine Didier

  • Bastien Gerby

  • Eric Delabesse

  • Marlène Pasquet

  • Cyril Broccardo

  • January 30, 2025

  • 0 min

Share

  • 1

    GATA2 is a key transcription factor in hematopoiesis, crucial for the generation and maintenance of hematopoietic stem and progenitor cells.

  • 2

    Germline GATA2 mutations are linked to various clinical presentations, including hematological malignancies and immunological defects.

  • 3

    Gata2R396Q/+ mice exhibit increased long-term hematopoietic stem cells but show functional impairments related to exhaustion and hyporesponsiveness.

  • 4

    A distinct subset of long-term HSCs predominantly expresses the mutated Gata2 allele, indicating a link between HSC function and allele-specific expression.

  • 5

    The study enhances understanding of GATA2 deficiency syndrome and its impact on hematopoietic tissue in patients with GATA2 germline mutations.

Original Source(s)

GATA2 mutated allele specific expression is associated with a hyporesponsive state of HSC in GATA2 deficiency syndrome

  • by Laetitia Largeaud, Vincent Fregona, Laura A. Jamrog, Camille Hamelle, Stéphanie Dufrechou, Naïs Prade, Esmaa Sellam, Pauline Enfedaque, Manon Bayet, Sylvie Hébrard, Mathieu Bouttier, Christine Didier, Bastien Gerby, Eric Delabesse, Marlène Pasquet, Cyril Broccardo

  • January 30, 2025

Related Content

The clinical relevance of sole loss of chromosome Y in myeloid neoplasms

Using period analysis to timely provide serial data on long-term survival for patients with hematological malignancies from Taizhou, Eastern China

Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants

Dana-Farber Cancer Institute’s adult stem cell transplant program and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center’s pediatric stem cell transplant program have once again received exceptional ratings from the Center for International Blood & Marrow Transplant Research (CIBMTR), earning a +1 performance score, the highest possible designation, on their annual center-specific survival reports.

  • by

  • December 17, 2025

  • 4 min